BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
8/27/2014 9:47:00 AM | Browse: 1281 | Download: 996
Publication Name World Journal of Clinical Urology
Manuscript ID 10069
Country/Territory Japan
Received
2014-03-11 21:17
Peer-Review Started
2014-03-12 08:56
To Make the First Decision
2014-04-28 14:27
Return for Revision
2014-04-30 20:11
Revised
2014-05-11 20:54
Second Decision
2014-06-18 15:00
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2014-06-18 15:18
Articles in Press
2014-06-18 15:43
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2014-07-09 13:53
Publish the Manuscript Online
2014-07-19 21:43
ISSN 2219-2816 (online)
Open Access
Copyright
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Urology & Nephrology
Manuscript Type Observational Study
Article Title Bone markers predict survival in castration-resistant prostate cancer patients treated with docetaxel
Manuscript Source Invited Manuscript
All Author List Takumi Endo, Naoto Kamiya, Hiroyoshi Suzuki, Ryo Oka, Fang-Ching Lee, Takanobu Utsumi, Masashi Yano, Shuichi Kamijima, Koji Kawamura, Takashi Imamoto and Tomohiko Ichikawa
Funding Agency and Grant Number
Funding Agency Grant Number
Ministry of Education, Culture, Sports, Science and Technology, Tokyo, Japan 22591761
Ministry of Education, Culture, Sports, Science and Technology, Tokyo, Japan 23791792
Corresponding Author Naoto Kamiya, Lecturer, Department of Urology, Toho University Sakura Medical Center 564-1 Shimo-shizu, Sakura-shi, Chiba 285-8741, Japan. E-mail: naoto.kamiya@med.toho-u.ac.jp
Key Words Prostate cancer; Docetaxel chemotherapy; Carboxy-terminal pyridinoline cross-linked telopeptide parts of type-1 collagen; Alkaline phosphatase; Prognostic factor
Core Tip This study examined the relationship between clinicopathological features and serum levels of carboxy-terminal pyridinoline cross-linked telopeptide parts of type-1 collagen (1CTP) and alkaline phosphatase (ALP) in castration-resistant prostate cancer patients treated with docetaxel. Patients were divided into two groups according to mean + SD of serum 1CTP (8.2 ng/mL) and ALP (538.2 IU/L) levels at the start of docetaxel chemotherapy. Patients with lower levels of serum 1CTP and ALP had significantly better survivals than those with higher serum levels. Serum levels of 1CTP and ALP are predictors of survival in patients with CRPC who are treated with docetaxel.
Publish Date 2014-07-19 21:43
Citation Endo T, Kamiya N, Suzuki H, Oka R, Lee FC, Utsumi T, Yano M, Kamijima S, Kawamura K, Imamoto T, Ichikawa T. Bone markers predict survival in castration-resistant prostate cancer patients treated with docetaxel. World J Clin Urol 2014; 3(2): 139-143
URL http://www.wjgnet.com/2219-2816/full/v3/i2/139.htm
DOI http://dx.doi.org/10.5410/wjcu.v3.i2.139
Full Article (PDF) WJCU-3-139.pdf
Full Article (Word) WJCU-3-139.doc
Manuscript File 10069-Review.doc
Answering Reviewers 10069-Answering reviewers.pdf
Copyright License Agreement 10069-Copyright assignment.pdf
Peer-review Report 10069-Peer review(s).pdf
Scientific Misconduct Check 10069-CrossCheck.jpg
Scientific Editor Work List 10069-Scientific editor work list.pdf